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Aspirin-exacerbated respiratory disease (AERD) is explained in part by over-expression of 5-lipoxygenase, leukotriene C4 synthase
(LTC4S) and the cysteinyl leukotriene (CysLT) receptors (CysLT1 and 2), resulting in constitutive over-production of CysLTs and
the hyperresponsiveness to CysLTs that occurs with aspirin ingestion. Increased levels of IL-4 have been found in the sinus mucosa
and nasal polyps of AERDsubjects. Previous studies demonstrated that IL-4is primarilyresponsible forthe upregulation of LTC4S
by mast cells and the upregulation of CysLT1 and 2 receptors on many immune cell types. Prostaglandin E2 (PGE2)a c t st op r e v e n t
CysLT secretion by inhibiting mast cell and eosinophil activation. PGE2 concentrations are reduced in AERD reﬂecting diminished
expression of cyclooxygenase (COX)-2. IL-4 can inhibit basal and stimulated expression of COX-2 and microsomal PGE synthase
1 leading to decreased capacity for PGE2 secretion. Thus, IL-4 plays an important pathogenic role in generating the phenotype
of AERD. This review will examine the evidence supporting this hypothesis and describe a model of how aspirin desensitization
provides therapeutic beneﬁt for AERD patients.
1.Introduction
Aspirin-exacerbated respiratory disease (AERD) is a syn-
drome characterized by asthma that, when present, is often
severe and can be associated with aggressive airway remod-
eling [1], the presence of extensive hyperplastic eosinophilic
sinusitis with nasal polyp (NP) formation [2], and intoler-
ancetoaspirinandothernonselectivecyclooxygenase(COX)
inhibitors [3–5]. A central feature of AERD is its association
with profound overproduction and overresponsiveness to
cysteinyl leukotrienes (CysLT) [6, 7]. These CysLTs have
important proinﬂammatory and proﬁbrotic eﬀects that con-
tribute both to the extensive hyperplastic sinusitis and nasal
polyposis that characterize AERD and to the severity of
these patients’ asthma [1, 8, 9]. Various cytokines have been
shown to modulate CysLT expression and responsiveness.
ThisreviewwillfocusontheroleofIL-4intheinductionand
maintenance of the AERD phenotype and consider impli-
cations of aspirin desensitization in altering the leukotriene
synthesis and responsiveness pathways.
2.DysregulationofCysteinylLeukotriene
Production in AERD
The overproduction of CysLTs in part reﬂects the increased
expression of its primary synthesis enzymes 5-lipoxygenase
(5-LO) and leukotriene C4 synthase (LTC4S). Upregulation
of these enzymes is readily observed in the lungs and nasal
polyps of AERD subjects [8, 10–12]. The overexpression
of these enzymes results in constitutive excess production
of the CysLTs as can be demonstrated in bronchoalveolar
lavage samples or through quantiﬁcation of urinary LTE4
[6, 7]. It is this upregulation of CysLT synthesis pathways2 Journal of Allergy
that underlies the observed life-threatening surge in CysLT
secretion following ingestion of aspirin or other non-
steroidal anti-inﬂammatory drugs (NSAIDs) in AERD [13–
16].
3. IL-4Dysregulationof LTC4S
Several cell types including mononuclear phagocytes, ba-
sophils, mast cells, and eosinophils express LTC4Sa n d
are thereby capable of CysLT production and secretion.
Mast cells typically express modest levels of LTC4S and its
upregulation can be mediated by IL-4 (but not by IL-5 or IL-
13) [17]. However, studies investigating the source of CysLTs
in AERD have suggested that eosinophils might be the most
important cell type driving the observed overexpression of
LTC4S[ 11]. In our studies, we were not able to demonstrate
a cytokine mechanism for increasing LTC4S expression in
eosinophils. In part, this may reﬂect the short-lived nature
of circulating eosinophils and their limited capacity for gene
transcription and phenotypic modulation. Arguably, the
“aspirinsensitive”phenotypeofeosinophilsinAERDreﬂects
the impact of inﬂuences acting upon eosinophil progenitors
in the bone marrow or, as increasingly recognized, long-lived
transcriptionally active progenitors in the airway tissue itself
[18].
4.IL-4inAERD
Relatively little is known regarding the expression of IL-
4 in sinus disease. The best study examined subjects with
chronic hyperplastic eosinophilic sinusitis and nasal polyps,
separating them on the basis of being allergic or nonallergic.
IL-4 was prominently expressed in the tissue of the allergic
subgroup when compared to either healthy controls or the
nonallergic subgroup [19]. Examination of nasal secretions
from subjects with chronic sinusitis found higher levels of
IL-4 protein when compared with controls [20]. In another
study that looked at allergic subjects with chronic sinusitis,
IL-4 transcripts were found to be high in the ethmoid sinus
mucosa and nasal turbinate tissue [21]. To our knowledge,
however, speciﬁc expression of IL-4 in AERD has not been
delineated. Our studies have demonstrated elevated levels of
IL-4 expression at the mRNA and protein levels in AERD in
comparison to control sinus tissue (unpublished results).
5.CysLTReceptor DysregulationinAERD
AERD subjects also demonstrate markedly increased sensi-
tivity to CysLTs [22], reﬂecting in part their upregulation
of CysLT receptors [23]. The two well-characterized CysLT
receptors can be distinguished by their relative potency for
the CysLTs: CysLT1 receptor LTD4 > LTC4   LTE4 and
CysLT2 receptor LTD4 = LTC4   LTE4. The relative insen-
sitivity of either of these receptors to LTE4 is in contrast to
theuniquesensitivityofAERDsubjectstothislipidmediator
and has led to the suggestion that additional CysLT receptors
must exist. This is more extensively reviewed elsewhere
[24] and in the absence of deﬁnitive characterization, these
Table 1: IL-4 modulation of CysLT receptor mRNA expression on
leukocyte.
CysLT1 receptor CysLT2 receptor
Monocytes 1.6 ±0.42 .5 ±0.7†
Tl y m p h o c y t e s 4 .3 ±2.1† 18.9 ±10.1§
Bl y m p h o c y t e s 3 .5 ±0.6† 11.1 ±2.7†
Eosinophils 2.4 ±0.94 .2 ±1.5
∗P<0.05; †P<0.01; §P<0.001.
Quantitative polymerase chain reaction data, presented as fold change in
comparison to unstimulated cells, which was set at 1. See legend for Table 2
for details.
will not be further addressed here. CysLT type 1 receptors
are prominently expressed on airway smooth muscle [25]
and these receptors primarily mediate the CysLT-induced
bronchospasm associated with allergen exposure [26, 27].
The role of these receptors in bronchospasm following
aspirin ingestion, however, is not clear. Our studies, and
those of others, have shown varied distribution of the CysLT
receptors on peripheral blood leukocytes [28–31]. While
both receptors are widely expressed on eosinophils and mast
cells only CysLT1 receptors can be found on neutrophils.
Further,veryfewcirculatingTlymphocytesnormallyexpress
either class of receptor (∼4–8%) [28, 29, 31]. Interestingly,
whilethe CysLT1receptorhasbeen foundonlung ﬁbroblasts
as well, nasal polyp-derived ﬁbroblasts express neither the
C y s L T 1n o r2r e c e p t o r s[ 32].
6.IL-4DysregulationofCysLT1and2Receptors
As with LTC4S expression, the expression of the CysLT re-
ceptors is tightly regulated by cytokines, including, most
prominently, IL-4. IL-4 upregulates cell surface expression
of both CysLT1 and CysLT2 receptors on mast cells [33,
34]. Similarly, IL-4 stimulates cell surface expression of the
CysLT1 receptor on monocytes and CysLT2 receptors on
endothelial cells [35]. We investigated modulation by IL-4 of
CysLT receptor expression on peripheral blood mononuclear
cells and eosinophils [31]. The most impressive results
were observed for IL-4 stimulation of the CysLT2 recep-
tor. Signiﬁcant increases in expression of CysLT2 receptor
transcripts were seen on T and B lymphocytes, monocytes,
and eosinophils. Additionally, IL-4 signiﬁcantly upregulated
CysLT1 receptor transcript and protein expression on T and
B cells (Table 1 and Figure 1). This increased expression in
secondarytoIL-4stimulationismechanisticallyexplainedby
the identiﬁcation of a STAT6 response element in the CysLT1
receptor promoter region [36].
7.Prostaglandin(PG)E2 andPGE2 Receptor
DysregulationinAERD
In addition to modulation of CysLTs, the pathophysiology
of AERD also involves downregulation of the prostaglandin
synthesis pathway. PGE2 displays both pro- and anti-
inﬂammatoryfunctionsreﬂectingitsabilitytointeractwith4
distinct receptors (EP1–4) each having various activating orJournal of Allergy 3
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Figure 1: Cytokine modulation of cysteinyl leukotriene receptor
protein expression on T cells. T cells were separated from blood
using magnetic bead aﬃnity chromatography and stimulated with
20ng/mL IL-4 for 16hrs before cells were collected for analysis.
Cellsurfaceexpressionof theCysLTR1receptorwas evaluated using
rabbit polyclonal anti-CysLTR1 followed by labeling with FITC-
conjugated goat anti-rabbit IgG. Isotype control is shown in white,
unstimulated in black, and IL-4 stimulated in gray. Reprinted with
permission of the American Thoracic Society [31].
inhibitory functions. The ability of PGE2 acting through EP2
receptors to block eosinophil and mast cell degranulation
is central to the pathogenesis of AERD and it has been
shown that patients with AERD constitutively display low
levels of PGE2 [12, 37]. The further reduction of tissue
PGE2 concentrations by aspirin and other NSAIDs through
COX inhibition precipitates the activation of these cells in
AERD, and infusion of PGE2 protects against these non-
IgE-mediated reactions [38, 39]. The sensitivity of AERD
patientstolowtissuePGE2 concentrationsisampliﬁedbythe
reduced expression of the anti-inﬂammatory EP2 receptors
also observed in this condition [40].
Several studies have investigated the mechanism behind
the reduced levels of PGE2 in these patient and have in-
dicated a correlation with a decrease in the responsible
upstream enzymes. The production of PGE2 from arachi-
donic acid involves the sequential synthesis of PGG2/PGH2
by the two cyclooxygenase enzymes (COX-1 and COX-
2) followed by the synthesis of PGE2 by the microsomal
PGE2 synthases (mPGES-1, mPGES-2) and cytosolic PGE2
synthase (cPGES). COX-2 mRNA and protein expression
are diminished in NPs of subjects with AERD [12, 41, 42].
Table 2: PgE2 metabolic pathway gene expression in control and
AERD tissue.
Gene Control ΔCT
1 AERD ΔCT ΔΔCT (2ΔΔCT)2
COX-1 10.5 ±0.41 11.3 ±2.1 −0.8 (.57)
COX-2 6.0 ±0.67 .9 ±2.8∗ −1.9 (.27)
mPGES-1 4.0 ±0.75 .0 ±0.5 −1( . 5 )
mPGES-2 2.8 ±0.84 .5 ±0.4∗ −1.7 (.31)
cPGES −0.1 ±0.60 .0 ±0.5 +0.1 (1.07)
∗P<0.05.
1Quantitiatve polymerase chain reaction data are presented as ΔCT,w h i c h
is the diﬀerence in threshold cycle of expression of each gene compared to
housekeeping gene (each cycle corresponds to ∼1log 2 diﬀerence in mRNA
concentration; a higher ΔCT represents less mRNA).
2ΔΔCT is the diﬀerence in ΔCT of gene expressed in control compared to
AERD tissue.
2ΔΔCT is the relative expression of gene in AERD compared to control tissue.
Our studies have conﬁrmed this diminished expression of
COX-2 (Table 2 and [43]). We found no signiﬁcant change
in COX-1 or cPGES transcript expression but, along with
COX-2, did show diminished expression of mPGES-2 and
a trend towards diminished mPGES-1 expression (Table 2).
It is mPGES-1 that is most relevant to PGE2 production in
inﬂammatory disorders such as AERD as it is functionally
coupled with COX-2 [44]. In general, mPGES-2 is thought
to be primarily expressed by the heart and brain and the
relevance of this dysregulation in AERD is unclear and
m a ym e r e l yr e ﬂ e c tt h ed i ﬀerent histologies of control sinus
epithelium and AERD NPs.
Diminished COX-2 expression and the reduced capacity
to synthesize PGE2 contributes to the severity of inﬂam-
mation observed in AERD and accentuates the sensitivity
of these individuals to the inhibition of PGE2 synthesis
associated with aspirin and other NSAIDs. This may also
explain the paradoxical absence of symptoms in AERD
patients that are typical in other forms of chronic sinusitis,
suchaspain andpressure.Withthis relative absenceofCOX-
2, AERD subjects become dependent upon COX-1 for the
PGE2 that is necessary to restrain mast cell and eosinophil
activation. Most AERD patients tolerate selective COX-2
inhibitors supporting this concept regarding the unique
importance of COX-1-derived PGE2.
8.IL-4DysregulationofPGE2
Synthesis Pathways
We investigated the molecular mechanism underlying inhi-
bition of PGE2 synthesis pathways in AERD, focusing on
inﬂuences of IL-4, reﬂecting again, its prominent expres-
sion in AERD, its previously described inﬂuences on the
prostaglandin metabolic pathways [45, 46], and its involve-
ment in the other facets of arachidonate dysregulation that
have been previously discussed. For example, in contrast
to IL-4 and despite being highly expressed in AERD, IL-
5 did not inﬂuence PGE2 production or responsiveness in
our studies (unpublished data). Our studies were performed
on nasal polyp-derived ﬁbroblasts, mononuclear phagocytic4 Journal of Allergy
Table 3: IL-4 modulation of PgE2 metabolic pathway gene ex-
pression.
COX-1 COX-2 mPGES-1
Monocytes 1.1 ±0.70 .3 ±0.2† 0.2 ±0.1†
Fibroblasts 0.6 ±0.70 .3 ±0.1† 0.5 ±0.1
Eosinophils 0.6 ±0.60 .7 ±0.71 .0 ±0.5
Quantitative polymerase chain reaction data, presented as fold change in
comparison to unstimulated cells, which was set at 1. †P<0.01.
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Figure 2: COX-2 protein expression in resting and LPS-stimulated
monocytes. Monocytes were isolated from blood by magnetic
bead puriﬁcation. Cells were treated with IL-4 (10ng/mL), IL-13
(10ng/mL), or LPS (1μg/mL) for 24hrs and whole cell lysates
collected. Proteins were separated on a 10% SDS acrylamide gel and
transferred to nitrocellulose. The membrane was probed with anti-
COX-2 and then stripped and reprobed with anti-β-actin.
cells, and eosinophils. Monocytes were utilized both as
representative inﬂammatory cells, but also because PGE2 is
theirdominantprostaglandinproduct.Signiﬁcantinhibition
of COX-2 and mPGES-1 (but not COX-1) mRNA expression
was observed in response to IL-4 (Table 3). This appears to
be a generalized eﬀect of IL-4 insofar as similar inhibition
was also observed in ﬁbroblasts. Similar to IL-5, IL-13 also
had no biological eﬀect (not shown). No inﬂuence of IL-
4 was observed in eosinophils. This may be a function of
the low levels of COX-2 expressed in these cells, whose
primaryarachidonateproductaretheCysLTs,butagain,may
also reﬂect our use of terminally diﬀerentiated cells. The
IL-4 eﬀect on monocyte mRNA was further extended to
expression of COX-2 protein as evaluated by Western blot.
While low basal protein levels of COX-2 were observed, IL-
4 (and not IL-13) inhibited LPS-stimulated COX-2 protein
expression (Figure 2).
Inhibition of COX-2 and mPGES-1 synergize to result in
dramatically less stimulated PGE2 secretion by monocytes
(Figure 3). Thus, in addition to upregulating CysLT path-
ways, IL-4 contributes to the sensitivity of AERD patients by
the inhibition of PGE2 production by aspirin/NSAIDs and,
inparticular,tononselective(COX-1andCOX-2)inhibitors.
However, it is necessary to remark that more than just loss of
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Figure 3: IL-4 inhibits monocyte PGE2 secretion. IL-4 was added
to the cells (10ng/mL) alone or either with LPS (1μg/mL) or IL-
1β (10ng/mL). Cells were incubated for 24hrs before supernatants
were collected. PGE2 levels were measured by ELISA and reported
as pg/mL [43].
the tempering inﬂuences of PGE2 underlies these reactions,
otherwise all asthmatics and, indeed, even healthy subjects
would react to aspirin/NSAID ingestion with activation of
their mast cells and eosinophils. Clearly, additional currently
uncharacterized biochemical mechanisms, in addition to the
relatively low levels of EP2 previously mentioned, must be
uniquely driving the tendency of these compounds to trigger
the mast cell, eosinophil, and perhaps other inﬂammatory
cells in AERD.
9. Aspirin Desensitization for
AERD—Implications for IL-4
Aspirin desensitization is an eﬀective treatment for AERD
and has been associated with diminished need for nasal
endoscopic surgery, improved sense of smell, fewer bouts
of acute sinusitis, reduced need for oral corticosteroids,
and less severe asthma [3, 47, 48]. The molecular mecha-
nism of the beneﬁcial eﬀects of aspirin has not been de-
termined, but we believe this could be related to the ability
of this compound to inhibit the biological activities of
IL-4. Consistent with this concept are the observations
that successful aspirin desensitization is associated with
reversal of many of the IL-4-modulated features of AERD
discussed above, including the ability of desensitization to
downregulate both CysLT1 receptor expression [22, 23]a n d
leukotriene synthesis [49] and reverse the inhibition of the
PGE2 synthesis pathway; presumably by blocking the IL-4Journal of Allergy 5
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Figure4:EMSAforSTAT6.(a)EMSAswereperformedusing 32P-labeledoligomerscomprisingtheSTAT6sitewithintheCysLT1Rpromoter.
NuclearextractswerepuriﬁedfromTHP-1mononuclearcelllinesintherestingstate,IL-4stimulated(10ng/mL),andIL-4stimulatedinthe
additional presence of aspirin (10mM). STAT6 binding was evaluated by performing EMSAs in the presence of 100–300-fold molar excess
unlabeled STAT6 consensus sequence (comprising the ε heavy chain promoter) or a mutated STAT6 consensus sequence. EMSAs were also
performed using STAT6, phosphoSTAT6, and, as a control, STAT4 antibodies. (b) Relevance to normal tissue was evaluated using nuclear
extracts prepared as above, derived from enriched peripheral blood-derived mononuclear phagocytes [43].
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Figure 5: Western hybridization of nuclear extracts. Nuclear extracts obtained as described for Figure 4 were electrophoresed on a 10%
SDS polyacrylamide gel and transferred to a nitrocellulose membrane. Presence of phosphoSTAT6 was determined via probing with anti-
phosphoSTAT6 antibodies and a secondary peroxidase-labeled antibody [43].
induced-inhibition of mPGES-1 synthesis (Tanya Laidlaw,
personal communication). The mechanism by which aspirin
might block these eﬀects is not immediately obvious. Aspirin
(and other NSAIDs) are known to have oﬀ-target eﬀects
(eﬀects not related to cyclooxygenase inhibition) including
modulation of nuclear traﬃcking of numerous transcription
factors such as NFAT, NF-κB, and STAT6 [50–52]. Many of
these oﬀ-target eﬀects of aspirin only occur at signiﬁcantly6 Journal of Allergy
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Figure 6: Summary of IL-4 activity on the leukotriene and prostaglandin synthesis pathways. Activation of gene synthesis by IL-4 is shown
in pink while inhibition of gene synthesis by IL-4 is shown in red.
higher concentrations than those required for COX-1 or
COX-2 inhibition [51]. The concentration of aspirin known
to be eﬀective after aspirin desensitization (up to 1300mg/d)
is somewhat higher than that required to inhibit COX-1 or
COX-2, consistent with the concept that aspirin could be
acting through one of these COX-independent pathways. Of
relevance to our work, aspirin is known to directly inhibit
T cell IL-4 expression [53]. Recently, continuous ingestion
of aspirin for 6 months following desensitization has been
shown to reduce sputum IL-4 levels [54]. Alternatively, we
focused on recognition that engagement of the IL-4 receptor
byIL-4 induces the activation of STAT6 via the Janus kinases.
This STAT6 activation is critical for many of the biological
activities of IL-4. As mentioned, a STAT6 site in the CysLT1
receptor promoter has been identiﬁed and was shown to
be involved in IL-4-mediated transcription regulation [36].
Similarly, a putative STAT6 site has been identiﬁed in
the LTC4S gene (Bing Lam, unpublished). Previous studies
demonstrate that aspirin inhibits the activation of STAT6
[55]. These observations suggested to us that aspirin may
produce its clinical utility in AERD through direct inhibition
of the IL-4-activated STAT6 pathway. Aspirin hypersensi-
tivity in AERD reﬂects inhibition of cyclooxygenase and as
such also occurs with other COX inhibitors [56]. Although
desensitization can be induced to other COX inhibitors, it is
not established whether the therapeutic beneﬁt that follows
desensitization reﬂects COX inhibition or some of these
otheroﬀ-targetanti-inﬂammatoryeﬀectsofNSAIDsandsal-
icylates.
10. AspirinModulationof STAT6
Nuclear Trafﬁcking
Our studies investigated the inhibition by aspirin and
other NSAIDs of the STAT6-mediated regulation of the
CysLT1 receptor and LTC4Sg e n e s[ 43]. In a dose-dependent
fashion, aspirin inhibited transcription of IL-4-induced
CysLT1 receptor expression (not shown). Subsequently, via
electrophoretic mobility shift assays (EMSA) we conﬁrmed
thepresenceofSTAT6binding-siteswithinboththeCysLT1R
(Figure 4)a n dL T C 4S promoters (not shown).
The presence of a mobility shift speciﬁcally mediated
by STAT6 was conﬁrmed by the ability of molar excess
unlabeledDNAprobes,comprisingtheSTAT6sitewithinthe
εheavychainpromoter,toblockbinding—butnotamutated
version of this STAT6 probe. That this shift was produced by
pSTAT6 was further conﬁrmed using anti-STAT6 and anti-
pSTAT6 antibodies. These results were extended to other
NSAIDs including ketorolac, but not sodium salicylate (not
shown). Ketorolac has been successfully utilized to diagnosis
aspirin intolerance [56] and these observations suggest a
plausible basis for it to have clinical eﬃcacy in AERD. The
mechanism by which aspirin blocks STAT6 expression is not
known, but has been suggested to involve nuclear traﬃcking
and recycling of transcription factors [51]. Our studies do
notdistinguishwhetheraspirinactstoeitherblockinduction
of pSTAT6 or traﬃcking of newly activated pSTAT6 into
the nucleus. However, our Western hybridization data do
conﬁrm the absence of functional pSTAT6 protein within theJournal of Allergy 7
nuclei of aspirin-treated cells (Figure 5). Even more impres-
sive, was the inhibition provided by ketorolac, supportive of
recent ﬁndings regarding the eﬃcacy of this compound in
therapeuticdesensitizationofAERD[57].Thesedatathereby
provide evidence that the CysLT1 receptor and LTC4Sp r o -
moters have STAT6 binding sites that are occupied following
IL-4 induction and inhibited by aspirin. As such, aspirin
desensitization may provide eﬀective therapy for AERD, at
leastinpart,throughmitigationofSTAT6activation,thereby
downregulating the leukotriene pathways—as is observed
clinically in successfully desensitized subjects.
Countering the argument that aspirin may function in
AERD as an IL-4-STAT6 antagonist is the lack of an obvious
recognition of its utility in aspirin-tolerant asthma or even
allergic rhinitis; disorders that arguably also involve IL-4
and STAT6 expression. It could be disputed that if aspirin
is an eﬀective anti-IL-4 agent it should be eﬀective in all
asthmatics. A subset of asthmatics is recognized who have
aspirin-responsive asthma [58] and aspirin may have modest
eﬃcacy in patients with chronic sinusitis without aspirin
intolerance (Donald Stevenson, unpublished). However,
AERDisadistinctdisorderfromaspirin-tolerantasthmaand
these subjects are unique in their production of and sen-
sitivity to leukotrienes. Eﬃcacy of aspirin desensitization
in AERD may therefore reﬂect the heightened importance
of these leukotriene-dependent and, by extension, aspirin-
responsive mechanisms in AERD. For example, leukotriene
modiﬁers, in particular leukotriene synthesis inhibitors,
seem uniquely eﬃcacious in AERD in comparison to aspirin
tolerant asthmatics [59]. Furthermore, the relative lack of
eﬃcacy of aspirin in aspirin-tolerant asthmatics, despite its
putative ability to block IL-4, parallels the failure of IL-4-
targetingbiotherapeuticsinthesesubjects(althoughsuggests
that perhaps these agents would have greater eﬃcacy if used
in AERD).
11. Summary
While the exact mechanisms driving AERD are not fully
understood, part of the explanation is the marked overex-
pression of the 5-LO and LTC4S genes, resulting in con-
stitutive overproduction of CysLTs, and the decrease in
PGE2 production that prevents mast cell and eosinophil
activation. These studies strongly suggest that AERD is
derived, at least in part, from either the increased production
or hyperresponsiveness to IL-4, although no obvious mecha-
nism underlying this dysregulation has been identiﬁed. This
increased expression of an IL-4 signature, as summarized
in Figure 6, can have activating and inhibitory eﬀects on
gene expression in the LT and PG pathways. The net
result of enhanced IL-4 levels is to increase synthesis of
and responsiveness to LTs, while blocking production of
protective PGE2. Compounds that target these molecules
may lead to new therapeutic options for the treatment of
AERD.
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